EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The Megacomplex protects ER-alpha from degradation by Fulvestrant in epithelial ovarian cancer

Sushil Kumar Jaiswal, Kevin Fedkenheuer, Ronak Khamar, Hua Tan, Valer Gotea, Sonam Raj, Michael Fedkenheuer, Abdel Elkahloun, Ming Zhao, Lisa M Jenkins, Christina M Annunziata, Laura Elnitski

Cancer Letters · 2025

DOI: 10.1016/j.canlet.2024.217129 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Sushil Kumar Jaiswal und 11 weiteren Autor:innen. Beteiligte Einrichtung: Translational and Functional Genomics Branch, National Human Genome Research Institute, Bethesda, MD, 20892, USA. Hauptthemen laut MEDLINE: Estrogen Receptor alpha, Fulvestrant, Carcinoma, Ovarian Epithelial, Ovarian Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Intramural NIH HHS, NCI, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian cancer, a significant contributor to cancer-related mortality, exhibits limited responsiveness to hormonal therapies targeting the estrogen receptor (ERα). This study aimed to elucidate the mechanisms behind ERα resistance to the therapeutic drug Fulvestrant (ICI182780 or ICI). Notably, compared to the cytoplasmic version, nuclear ERα was minimally degraded by ICI, suggesting a mechanism for drug resistance via the protective confines of the nuclear substructures. Of these substructures, we identified a 1.3 MDa Megacomplex comprising transcription factors ERα, FOXA1, and PITX1 using size exclusion chromatography (SEC) in the ovarian cancer cell line, PEO4. ChIP-seq revealed these factors colocalized at 6775 genomic positions representing sites of Megacomplex formation. Megacomplex ERα exhibited increased resistance to degradation by ICI compared to cytoplasmic and nuclear ERα. A small molecule inhibitor of active chromatin and super-enhancers, JQ1, in combination with ICI significantly enhanced ERα degradation from Megacomplex as revealed by SEC and ChIP-seq. Interestingly, this combination degraded both the cytoplasmic as well as nuclear ERα. Pathway enrichment analysis showed parallel results for RNA-seq gene sets following Estradiol, ICI, or ICI plus JQ1 treatments as those defined by Megacomplex binding identified through ChIP-seq. Furthermore, similar pathway enrichments were confirmed in mass-spec analysis of the Megacomplex macromolecule fractions after modulation by Estradiol or ICI. These findings implicate Megacomplex in ERα-driven ovarian cancer chromatin regulation. This combined treatment strategy exhibited superior inhibition of cell proliferation and viability. Therefore, by uncovering ERα's resistance within the Megacomplex, the combined ICI plus JQ1 treatment elucidates a novel drug treatment vulnerability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Estrogen Receptor alphaFulvestrantCarcinoma, Ovarian EpithelialOvarian NeoplasmsHumansFemaleCell Line, TumorDrug Resistance, NeoplasmTriazolesProteolysisAntineoplastic Agents, HormonalHepatocyte Nuclear Factor 3-alphaAzepines

Stichwörter der Autor:innen

BRD4 inhibitorChIP-seqDrug resistanceEstrogen receptorGel filtrationICI182780JQ1MegacomplexOvarian cancerSuper-enhancer

Substanzen

Estrogen Receptor alphaFulvestrantESR1 protein, humanTriazoles(+)-JQ1 compoundAntineoplastic Agents, HormonalHepatocyte Nuclear Factor 3-alphaAzepines

Autor:innen und Institutionen

  • Translational and Functional Genomics Branch, National Human Genome Research Institute, Bethesda, MD, 20892, USA.
  • Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD, 20892, USA.
  • Molecular Immunology and Inflammation Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Microarrays and Single-Cell Genomics Core, National Human Genome Research Institute, Bethesda, MD, 20892, USA.
  • Proteins and Chemistry Core, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, Rockville, MD, 20852, USA.
  • Mass Spectrometry Resource, Laboratory of Cell Biology, National Cancer Institute, Bethesda, MD 20892, USA.

Förderung

  • Intramural NIH HHS
  • NCI
  • National Institutes of Health
  • National Human Genome Research Institute

Zitieren

APA

Jaiswal, S. K., Fedkenheuer, K., Khamar, R., Tan, H., Gotea, V., Raj, S., Fedkenheuer, M., Elkahloun, A., Zhao, M., Jenkins, L. M., Annunziata, C. M., & Elnitski, L. (2025). The Megacomplex protects ER-alpha from degradation by Fulvestrant in epithelial ovarian cancer. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217129

Vancouver

Jaiswal SK, Fedkenheuer K, Khamar R, Tan H, Gotea V, Raj S, et al. The Megacomplex protects ER-alpha from degradation by Fulvestrant in epithelial ovarian cancer. Cancer Letters. 2025. doi:10.1016/j.canlet.2024.217129

BibTeX
@article{Jaiswal2025,
  author = {Jaiswal, Sushil Kumar and Fedkenheuer, Kevin and Khamar, Ronak and Tan, Hua and Gotea, Valer and Raj, Sonam and Fedkenheuer, Michael and Elkahloun, Abdel and Zhao, Ming and Jenkins, Lisa M and Annunziata, Christina M and Elnitski, Laura},
  title = {The Megacomplex protects ER-alpha from degradation by Fulvestrant in epithelial ovarian cancer},
  journal = {Cancer Letters},
  year = {2025},
  doi = {10.1016/j.canlet.2024.217129}
}
Kostenlos starten →